News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–21
Matches
21
Sources here
6
Companies here
1
Search results Stored financial headlines

Active search

21 matching headlines

Ticker or company: KYEMain company stories
Clear
Latest

Investing.com Nigeria Deals and strategy

Skye Bioscience to acquire Redx Pharma in $125M deal By Investing.com

Skye Bioscience announced its definitive agreement to acquire Redx Pharma through a scheme of arrangement under U.K. law for an approximate $125 million deal. The merged entity will be known as Fibrx Therapeutics Inc., trading on Nasdaq, and will be led by Redx's current management. The deal, expected to close in Q4 2026, includes various financing components and …

Main company 🇺🇸 United States
Read at Investing.com Nigeria
Sharemaestro market context Price below Trend Line 52 weeks -84.7% SKYE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Just inNext headlines
Investing.com Nigeria Market update Main company 🇺🇸 United States

Form 8K Skye Bioscience Inc For: 14 August By Investing.com

This article reports that Skye Bioscience Inc. filed a Form 8K on August 14. The filing is a standard disclosure document used by public companies to announce major events that shareholders should know about. The article provides no further details on the content of …

SKYE main company
Sharemaestro market context Price below Trend Line 52 weeks -84.7% SKYE stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

TradingView Deals and strategy Main company 🇺🇸 United States

Skye Bioscience to Acquire Redx; Secures $67.9M Financing and $22M Equity Line

Skye Bioscience is set to acquire Redx through a UK court-sanctioned scheme of arrangement, backed by a significant financing package. The deal includes a $67.9 million equity financing (potentially rising to $72.9 million), a $22.0 million equity line, and a $5.0 million warrant with …

SKYE main company
Sharemaestro market context Price below Trend Line 52 weeks -84.7% SKYE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
GlobeNewswire Deals and strategy Main company 🇺🇸 United States

Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings

Skye Bioscience and Redx Pharma have announced a definitive transaction agreement, forming a combined company named Fibrx Therapeutics, which will focus on developing novel small molecule medicines for fibrotic diseases. This merger is supported by approximately $125 million in financings, including a PIPE financing …

SKYE main company
Sharemaestro market context Price below Trend Line 52 weeks -84.7% SKYE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Deals and strategy Main company 🇺🇸 United States

Skye Bioscience (NASDAQ: SKYE) exits obesity trial, pursues Redx merger and $100M+ funding

Skye Bioscience is discontinuing its nimacimab obesity program and pursuing a merger with Redx Pharma to form Fibrx Therapeutics, Inc. This strategic shift addresses significant financial strains, as evidenced by a $23.3 million net loss and a substantial doubt about its ability to continue …

SKYE main company
Sharemaestro market context Price below Trend Line 52 weeks -84.7% SKYE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Deals and strategy Main company 🇺🇸 United States

Skye Bioscience, Inc. 2026: Revenue $178.2K, EPS ($0.27) — 10-Q Summary

Skye Bioscience, Inc. reported its 2026 quarterly results, showing revenue of $178.2K and a net loss of ($10.79M), leading to a diluted loss per share of ($0.27), which is an improvement over the prior year. The company also announced the termination of its CBeyond …

SKYE main company
Sharemaestro market context Price below Trend Line 52 weeks -84.7% SKYE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Analyst action Main company 🇺🇸 United States

Skye Bioscience Inc (SKYE) Stock News Today

This article provides an overview of Skye Bioscience Inc (SKYE) stock information on TradingKey, including its current market price, market cap, and links to financial data, stock scores, and analyst forecasts. It notes that more news about SKYE is expected soon. The page serves …

SKYE main company
Sharemaestro market context Price below Trend Line 52 weeks -84.7% SKYE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Skye Bioscience Inc (SKYE) Earnings Forecast: Future EPS & Revenue Growth Estimates

Skye Bioscience Inc (SKYE) has an earnings forecast score of 7.71, ranking 270th in its industry, with an average analyst price target of $10.00. Based on 7 analysts, the stock has a "Buy" rating with a potential upside of over 1450%. The company's previous …

SKYE main company
Sharemaestro market context Price below Trend Line 52 weeks -84.7% SKYE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

SKYE Q2'26 Earnings: EPS estimate is (0.24) USD

Skye Bioscience, Inc. (SKYE) is expected to release its Q2'26 earnings on August 7th. The company anticipates reporting revenue of 0 USD and an EPS of (0.24) USD for the quarter. This article provides a brief overview of the upcoming earnings announcement and historical …

SKYE main company
Sharemaestro market context Price below Trend Line 52 weeks -84.7% SKYE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TipRanks Earnings Main company 🇺🇸 United States

Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Report - Results, Call & Slides

Skye Bioscience (SKYE) reported its Q4 2025 earnings, missing consensus EPS expectations with an actual EPS of -$0.36 against a -$0.30 consensus. Revenue met expectations at $0.00. The company announced its earnings on March 10, 2026, after market close, with its next earnings report …

SKYE main company
Sharemaestro market context Price below Trend Line 52 weeks -84.7% SKYE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Skye Bioscience Inc expected to post a loss of 25 cents a share - Earnings Preview

Skye Bioscience Inc is projected to report a loss of 25 cents per share, according to this earnings preview. The full article provides more details on this financial forecast.

SKYE main company
Sharemaestro market context Price below Trend Line 52 weeks -84.7% SKYE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Skye Bioscience Inc (SKYE) Institutional Confidence

This article provides an overview of institutional confidence in Skye Bioscience Inc (SKYE), detailing the shares held by various institutional investors and the changes in their holdings. Key investors like 5AM Ventures, Versant Ventures, and Baker Bros. Advisors LP hold significant shares, while others …

SKYE main company
Sharemaestro market context Price below Trend Line 52 weeks -84.7% SKYE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

SKYE|Skye Bioscience Inc|Price:0.630|Chg%:+0.015

This article provides a detailed financial overview of Skye Bioscience Inc. (SKYE), including its income statement, balance sheet, and cash flow statement. It highlights key financial indicators, recent earnings per share (EPS), and revenue forecasts, alongside historical quarterly and annual data. The article also …

SKYE main company
Sharemaestro market context Price below Trend Line 52 weeks -84.7% SKYE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Skye Bioscience Inc (SKYE) Financial Health: Profitability & Balance Sheet Analysis

This article provides an analysis of Skye Bioscience Inc's (SKYE) financial health, scoring it at 7.00 out of 385 in the Biotechnology & Medical Research industry. While the company's financial status is robust, its operating efficiency is low. The article details various financial dimensions …

SKYE main company
Sharemaestro market context Price below Trend Line 52 weeks -84.7% SKYE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Skye Bioscience Inc (SKYE) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Skye Bioscience Inc (SKYE), noting its current valuation score of 6.94 within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -0.43 and indicates that relevant data for P/B and P/CF ratios have …

SKYE main company
Sharemaestro market context Price below Trend Line 52 weeks -84.7% SKYE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Skye Bioscience Inc (SKYE) Cash Flow

This article provides a detailed quarterly and annual cash flow statement for Skye Bioscience Inc (SKYE). It breaks down operating, investing, and financing cash flows, including specific figures for net income, capital expenditures, and changes in working capital across various fiscal quarters. The content …

SKYE main company
Sharemaestro market context Price below Trend Line 52 weeks -84.7% SKYE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Skye Bioscience Inc (SKYE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey attempts to provide a revenue breakdown for Skye Bioscience Inc (SKYE) by business segments and region. However, it states that the relevant financial data has not been disclosed by the company yet. As a result, no specific revenue figures or …

SKYE main company
Sharemaestro market context Price below Trend Line 52 weeks -84.7% SKYE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Market update Main company 🇺🇸 United States

Skye Bioscience, Inc. Revenue Breakdown – LSX:A3ES4X

This article provides a financial overview of Skye Bioscience, Inc. (LSX:A3ES4X) on TradingView. It appears to be an empty or incomplete financial data page, indicating no trades have occurred for the company and showing various navigation and information sections typical of a financial platform …

SKYE main company
Sharemaestro market context Price below Trend Line 52 weeks -84.7% SKYE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

SKYE Income Statement

This article provides a detailed quarterly and annual income statement for Skye Bioscience Inc (SKYE), allowing users to analyze its financial performance and operational efficiency. It covers metrics such as total revenue, operating expenses, R&D expenses, net income, and EPS over several fiscal years …

SKYE main company
Sharemaestro market context Price below Trend Line 52 weeks -84.7% SKYE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

SKYE|Skye Bioscience Inc|Price:0.652|Chg%:-0.023

Skye Bioscience Inc. (SKYE) shows healthy fundamentals and high growth potential, though its valuation is considered fair. Analysts rate the stock as "Buy" with a significant upside, but the stock price is expected to trend down in the medium term. The company is focused …

SKYE main company
Sharemaestro market context Price below Trend Line 52 weeks -84.7% SKYE stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context